You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Diabetes and other endocrinal, nutritional and metabolic conditions
  5. Metabolic conditions

Atidarsagene autotemcel for treating metachromatic leukodystrophy

  • Highly specialised technologies guidance
  • Reference number: HST18
  • Published:  28 March 2022
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Final evaluation determination
  2. Evaluation consultation
  3. Invitation to participate
  4. Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

History

Documents created during the development process.

Final evaluation determination

  • Final evaluation determination

  • Committee papers (PDF 1.1 MB)

    Published:
    04 February 2022
  • Final evaluation determination document (PDF 376 KB)

    Published:
    04 February 2022

Evaluation consultation

  • Evaluation consultation

  • Committee papers (PDF 7.89 MB)

    Published:
    09 July 2021
  • Public committee slides April 2021 (PDF 2.02 MB)

    Published:
    09 July 2021
  • Public committee slides June 2021 (PDF 1.01 MB)

    Published:
    09 July 2021
  • Evaluation consultation document (PDF 372 KB)

    Published:
    09 July 2021

Invitation to participate

  • Equality Impact Assessment (Guidance development) (PDF 123 KB)

    Published:
    23 September 2020
  • NICE's response to comments on the draft scope and provisional stakeholder list (PDF 585 KB)

    Published:
    23 September 2020
  • Final scope (PDF 194 KB)

    Published:
    23 September 2020
  • Final stakeholder list (PDF 225 KB)

    Published:
    23 September 2020

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

  • Draft scope pre referral (PDF 204 KB)

    Published:
    21 November 2019
  • Draft matrix pre referral (PDF 225 KB)

    Published:
    05 December 2019
Back to top